NCT00733616 - Efficacy and Safety Study of Combination Therapy With Docetaxel-oxaliplatin-capecitabine in Patients With Advanced Gastric Adenocarcinoma and Intermediate General Status | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions

Gastric Cancer

Interventions

DRUG

DOX: Docetaxel, oxaliplatin, Capecitabine

"* Docetaxel 40 mg/m2, iv infusion 60 minutes, day 1~* Oxaliplatin 80 mg/m2, iv infusion 120 minutes, day 1~* Capecitabine 625 mg/m2, bid, oral, continuous~ 6 cycles, every 3 weeks~Capecitabine will be given same dose (625mg/m2/bid) continuous in case no toxicity (no dose adjustment)"

Trial Locations (1)

Unknown

Spanish Cooperative Group for Gastrointestinal Tumour Therapy, Madrid